Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

To Evaluate Eye Installation-Tear Free

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02802917
Recruitment Status : Completed
First Posted : June 16, 2016
Last Update Posted : December 12, 2018
Sponsor:
Information provided by (Responsible Party):
Bayer

Brief Summary:
The primary objective of this study was to compare the human eye stinging potential of experimental formulas of sun care products [Sun Protection Factor (SPF) 50 Y49 091, SPF 50 X15 158, SPF 50 X15 160 and SPF 50 X57 162 compared to an industry standard shampoo mixture.

Condition or disease Intervention/treatment Phase
Sunscreening Agents Drug: SPF 50 Y49 091 (BAY 987516) Drug: SPF 50 X15 158 (BAY 987516) Drug: SPF 50 X15 160 (BAY 987516) Drug: SPF 50 X57 162 (BAY 987516) Other: J & J baby shampoo, X46 046 (control) Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 83 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Other
Official Title: Evaluation of the Stinging Potential of Products in Human Eyes
Actual Study Start Date : May 15, 2015
Actual Primary Completion Date : May 24, 2015
Actual Study Completion Date : May 24, 2015

Arm Intervention/treatment
Experimental: SPF 50 Y49 091
Subjects were given the control article (standard shampoo mixture, X46 046) in one eye and one of the test articles in the other eye according to the randomization schedule.
Drug: SPF 50 Y49 091 (BAY 987516)
5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye.

Other: J & J baby shampoo, X46 046 (control)
5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye.

Experimental: SPF 50 X15 158
Subjects were given the control article (standard shampoo mixture, X46 046) in one eye and one of the test articles in the other eye according to the randomization schedule.
Drug: SPF 50 X15 158 (BAY 987516)
5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye.

Other: J & J baby shampoo, X46 046 (control)
5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye.

Experimental: SPF 50 X15 160
Subjects were given the control article (standard shampoo mixture, X46 046) in one eye and one of the test articles in the other eye according to the randomization schedule.
Drug: SPF 50 X15 160 (BAY 987516)
5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye.

Other: J & J baby shampoo, X46 046 (control)
5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye.

Experimental: SPF 50 X57 162
Subjects were given the control article (standard shampoo mixture, X46 046) in one eye and one of the test articles in the other eye according to the randomization schedule.
Drug: SPF 50 X57 162 (BAY 987516)
5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye.

Other: J & J baby shampoo, X46 046 (control)
5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye.




Primary Outcome Measures :
  1. Subjective discomfort [ Time Frame: up to 10 days ]
    Score 0: No discomfort felt Score 1: Faint, barely perceptible discomfort Score 2: Mild, low intensity discomfort that does not prevent the subject from opening lids Score 3: Moderately intense discomfort that interferes with but does not prevent lid opening Score 4: Severe, very intense discomfort that makes voluntary lid opening difficult, requires force to pull lids apart, and results in the subject requesting washout of test article

  2. Objective lacrimation [ Time Frame: up to 10 days ]
    Score 0: No tearing or lid wetness above normal Score 1: Noticeable increase in moistness of lid edges - no frank tearing Score 2: Frank tearing - meager flow Score 3: Frank tearing - moderate flow Score 4: Frank tearing - copious flow

  3. Objective conjunctival inflammation [ Time Frame: up to 10 days ]
    Score 0: Inflammatory changes absent Score 1: Capillaries slightly more prominent than they were at time of baseline examination Score 2: Capillaries very prominent plus some diffuse conjunctival reddening Score 3: Vessels very prominent plus diffuse and confluent intense redness Score 4: Beefy redness and everted lids

  4. Objective cornea and iris inflammation [ Time Frame: up to 10 days ]
    Score 0: No effect detected with use of slit lamp Score 1: Barely perceptible clouding or pitting of cornea or thickening of iris detected via slit lamp Score 2: Faint clouding or pitting of cornea and/or thickening of the iris Score 3: Moderate clouding or pitting of cornea and/or thickening of the iris Score 4: Intense clouding or pitting of cornea and/or thickening of the iris



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy males or females, 18 to 60 years with no medical conditions of the eyes as determined by the subject's medical history and confirmed by an ophthalmologist
  • Subjects not under any doctor's care for ocular or peri orbital diseases
  • The subject will refrain from using contact lenses, any topical facial products, any eye drops, false eyelashes, make up, over the counter products, or cosmetics on their eyes, eyelids, eyelashes, or the periorbital areas of the face during the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02802917


Locations
Layout table for location information
United States, Florida
Saint Petersburg, Florida, United States, 33714
Sponsors and Collaborators
Bayer
Investigators
Layout table for investigator information
Study Director: Bayer Study Director Bayer

Additional Information:
Layout table for additonal information
Responsible Party: Bayer
ClinicalTrials.gov Identifier: NCT02802917     History of Changes
Other Study ID Numbers: 18271
First Posted: June 16, 2016    Key Record Dates
Last Update Posted: December 12, 2018
Last Verified: December 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Bayer:
Eye stinging potential